Neurotrophic factors and neuropathic pain

Curr Opin Pharmacol. 2001 Feb;1(1):66-72. doi: 10.1016/s1471-4892(01)00010-8.

Abstract

Neuropathic pain is a debilitating consequence of nerve damage. Existing treatment is largely ineffective. Current models of neuropathic pain recognise the importance of ectopic activity in primary sensory neurones impinging on a sensitised central nervous system. Neurotrophic factors have been shown to be neuroprotective for damaged sensory neurones, providing a rationale for testing their effects in neuropathic pain states. Recent data have demonstrated potent analgesic effects of one factor (glial cell line-derived neurotrophic factor) in animal models of neuropathy, and implicated changes in sodium channel alpha-subunits in the generation of afferent ectopic activity. The new findings provide a rational basis for the use of neurotrophic factors as a novel therapeutic treatment for neuropathic pain states.

Publication types

  • Review

MeSH terms

  • Animals
  • Glial Cell Line-Derived Neurotrophic Factor
  • Humans
  • Nerve Growth Factors / physiology*
  • Nerve Growth Factors / therapeutic use*
  • Nerve Tissue Proteins / therapeutic use
  • Neurons, Afferent / drug effects
  • Neurons, Afferent / pathology
  • Neuroprotective Agents / therapeutic use
  • Pain / drug therapy*
  • Pain / pathology*

Substances

  • GDNF protein, human
  • Glial Cell Line-Derived Neurotrophic Factor
  • Nerve Growth Factors
  • Nerve Tissue Proteins
  • Neuroprotective Agents